Cargando…

Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research

BACKGROUND: To assess healthcare processes during treatment of neovascular age-related macular degeneration (AMD) in patients under real-life conditions and evaluate efficacy of monthly visual acuity (VA) assessment in a pro re nata treatment regime. METHODS: A multicentre, prospective, non-interven...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wolf, Armin, Kampik, Anselm
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Medical Ophthalmology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3968520/ https://www.ncbi.nlm.nih.gov/pubmed/24424409 http://dx.doi.org/10.1007/s00417-013-2562-6

Ejemplares similares

Subretinal Neovascular Membrane in Wet Age-Related Macular Degeneration Managed With Intravitreal Ranibizumab
por: Sharma, Tanishq S, et al.
Publicado: (2021)

Comparative efficacy and safety of different regimens of ranibizumab for neovascular age-related macular degeneration: a network meta-analysis of randomised controlled trials
por: Zhao, Xinyu, et al.
Publicado: (2021)

Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration
por: Dikmetas, Ozlem, et al.
Publicado: (2022)

Patient experience of treatment decision making for wet age-related macular degeneration disease: a qualitative study in China
por: Bian, Wei, et al.
Publicado: (2019)

Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration
por: Chen, Youxin, et al.
Publicado: (2012)

Efficacy of ranibizumab combined with photodynamic therapy on wet age-related macular degeneration
por: Chen, Ling, et al.
Publicado: (2020)

A Comparative Study of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration: 12-Month Outcomes of Polish Therapeutic Program in Non-Tertiary Institution
por: Skrzypczak, Tomasz, et al.
Publicado: (2021)

Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration
por: García-Layana, Alfredo, et al.
Publicado: (2015)

Treatment of neovascular age-related macular degeneration: insights into drug-switch real-world from the Berlin Macular Registry
por: Riemer, Tommes, et al.
Publicado: (2023)

Exploring challenges to nutrition intervention adherence using COM-B model among patients with wet age-related macular degeneration: a qualitative study
por: Bian, Wei, et al.
Publicado: (2022)

Antiplatelet and anticoagulant therapy in patients with submacular hemorrhage caused by neovascular age-related macular degeneration
por: Weber, Constance, et al.
Publicado: (2022)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
por: Dervenis, Nikolaos, et al.
Publicado: (2016)

Reduction in choroidal thickness of macular area in polypoidal choroidal vasculopathy patients after intravitreal ranibizumab therapy
por: Nishide, Tadayuki, et al.
Publicado: (2013)

Macular Hole Formation After Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration
por: Mukherjee, Chandoshi, et al.
Publicado: (2015)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration [Corrigendum]
Publicado: (2016)

Age-Related Macular Degeneration: Epidemiology, Pathophysiology, Diagnosis, and Treatment
por: Vyawahare, Hrishikesh, et al.
Publicado: (2022)

A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration—the FALCON study
por: Holz, F. G., et al.
Publicado: (2022)

An Analysis of the Usage of Retinal Imaging Technology in the Detection of Age-Related Macular Degeneration
por: Riazi Esfahani, Parsa, et al.
Publicado: (2023)

Ranibizumab for choroidal neovascularization secondary to pseudoxanthoma elasticum: 4-year results from the PIXEL study in France
por: Mimoun, Gérard, et al.
Publicado: (2017)

Dietary intervention in patients with age-related macular degeneration: protocol for a randomised controlled trial
por: Tang, Diana, et al.
Publicado: (2019)

A Study of Correlates of Age-Related Macular Degeneration in Patients Attending a Tertiary Hospital
por: Mehta, Kervi, et al.
Publicado: (2022)

Age-Related Macular Degeneration: An Exponentially Emerging Imminent Threat of Visual Impairment and Irreversible Blindness
por: Chaudhuri, Madhurima, et al.
Publicado: (2023)

Co-existence of Age-Related Macular Degeneration and Diabetic Retinopathy in a Tertiary Referral Center in Greece
por: Bourouki, Evgenia, et al.
Publicado: (2022)

Patient perspectives and barriers in the treatment of neovascular age-related macular degeneration in Denmark: a qualitative study
por: Thinggaard, Benjamin Sommer, et al.
Publicado: (2023)

Healthcare experiences of patients with age-related macular degeneration: have things improved? Cross-sectional survey responses of Macular Society members in 2013 compared with 1999
por: Boxell, Emily M, et al.
Publicado: (2017)

Pain related to intravitreal injections for age-related macular degeneration: a qualitative study of the perspectives of patients and practitioners
por: Yiallouridou, Christina, et al.
Publicado: (2023)

Prognostic Factors of Early Morphological Response to Treatment with Ranibizumab in Patients with Wet Age-Related Macular Degeneration
por: Chrapek, Oldřich, et al.
Publicado: (2015)

Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration
por: Topal, Tuncay, et al.
Publicado: (2017)

Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis
por: Hernandez, Luis, et al.
Publicado: (2018)

Effectiveness of Community versus Hospital Eye Service follow-up for patients with neovascular age-related macular degeneration with quiescent disease (ECHoES): a virtual non-inferiority trial
por: Reeves, Barnaby C, et al.
Publicado: (2016)

Anti-VEGF therapies in the treatment of choroidal neovascularisation secondary to non-age-related macular degeneration: a systematic review
por: Stuart, Arabella, et al.
Publicado: (2015)

Clinical Wide-Field Retinal Image Deep Learning Classification of Exudative and Non-Exudative Age-Related Macular Degeneration
por: Tak, Nathaniel, et al.
Publicado: (2021)

Cross-sectional study evaluating burden and depressive symptoms in family carers of persons with age-related macular degeneration in Australia
por: Jin, Ivan, et al.
Publicado: (2021)

Eligibility for faricimab in a real-world neovascular age-related macular degeneration population: a cross-sectional study
por: Jern, Iréne, et al.
Publicado: (2022)

Faricimab Effectively Resolves Intraretinal Fluid and Preserves Vision in Refractory, Recalcitrant, and Nonresponsive Neovascular Age-Related Macular Degeneration
por: Cheng, Anny M, et al.
Publicado: (2023)

How does age-related macular degeneration affect real-world visual ability and quality of life? A systematic review
por: Taylor, Deanna J, et al.
Publicado: (2016)

Accuracy of a Self-monitoring Test for Identification and Monitoring of Age-related Macular Degeneration: A Diagnostic Case-control Study
por: Schmid, Martin K., et al.
Publicado: (2018)

Association of age-related macular degeneration on fracture risks among osteoporosis population: a nationwide population-based cohort study
por: Sun, Chi Chin, et al.
Publicado: (2020)

Combined Administration of Preoperative Intravitreal and Intraoperative Subretinal Recombinant Tissue Plasminogen Activator in Acute Hemorrhagic Age-related Macular Degeneration
por: Helaiwa, Khaled, et al.
Publicado: (2020)

Association between metformin use and the risk of age-related macular degeneration in patients with type 2 diabetes: a retrospective study
por: Jiang, Jingjing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ujvv6lm2qejj6nq2sqha710abf